^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IDH wild-type

    i
    Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble, IDH2, Isocitrate Dehydrogenase (NADP(+)) 2, Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial, Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial, Isocitrate Dehydrogenase [NADP], Mitochondrial, Oxalosuccinate Decarboxylase, NADP(+)-Specific ICDH, ICD-M, IDH, IDP, MNADP-IDH, D2HGA2, IDHM, IDPM
    Entrez ID:
    3417; 3418
    Related biomarkers:
    Expression
    Mutation
    Others
    1d
    SHINE-GLIO: Mental Health and Suicidality in Glioblastoma Patients in Germany (clinicaltrials.gov)
    P=N/A, N=176, Recruiting, University Hospital, Essen | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH wild-type
    3d
    MiR-124-3p Suppresses Glioma Cells Progression by Targeting STAT3/NAMPT and Inhibiting AKT/ERK Signaling. (PubMed, Curr Cancer Drug Targets)
    MiR-124-3p functions as a tumor suppressor in glioma by repressing STAT3/NAMPT-mediated AKT/ERK signaling, highlighting its potential as a diagnostic biomarker and therapeutic target for glioma management.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • NAMPT (Nicotinamide Phosphoribosyltransferase) • MIR124-3 (MicroRNA 124-3)
    |
    IDH wild-type
    4d
    GBM AGILE: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (clinicaltrials.gov)
    P2/3, N=2250, Recruiting, Global Coalition for Adaptive Research | N=1280 --> 2250
    Enrollment change
    |
    IDH wild-type
    |
    temozolomide • Stivarga (regorafenib) • lomustine • VT1021 • AZD1390 • Hepacid (pegargiminase) • paxalisib (GDC-0084) • dianhydrogalactitol (VAL-083) • Vyglxia (troriluzole) • tinostamustine (EDO-S101)
    5d
    Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy (clinicaltrials.gov)
    P1, N=20, Recruiting, Mayo Clinic | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    IDH wild-type
    7d
    Increased cortical excitability to transcranial magnetic stimulation at the brain-tumor interface of IDH1-mutant gliomas. (PubMed, Neurooncol Adv)
    The data demonstrate how molecular glioma characteristics affect peritumoral neuronal circuits. Modulating interactions at the BTI might pave the way for novel therapies.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH wild-type
    7d
    Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, IDH-wildtype. (PubMed, Neurooncol Adv)
    mGBM with MRI enhancement may represent undersampled or early/evolving hGBM. mGBM that are non-enhancing, present with seizures, prolonged time to diagnosis, absent CDKN2A/B alteration or +7/-10 may represent other IDH-wildtype entities.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    CDKN2A deletion • IDH wild-type
    7d
    Presence of IDH2 and TP53 mutations significantly reduces survival of patients with chondrosarcoma. (PubMed, Cancer)
    IDH2 and TP53 mutations are enriched in dedifferentiated CS and are significant, independent predictors of adverse survival, regardless of tumor grade. These findings support IDH2 mutation status as clinically meaningful prognostic biomarker that may allow risk stratification and clinical decision-making in CS patients.
    Retrospective data • Journal
    |
    TP53 (Tumor protein P53) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    TP53 mutation • IDH1 mutation • IDH2 mutation • IDH wild-type • IDH1 R132 • IDH2 R172
    7d
    Azeliragon in MGMT Unmethylated Glioblastoma (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Cantex Pharmaceuticals | Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Sep 2024 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation • IDH wild-type
    |
    azeliragon (TTP488)
    7d
    CITADEL-123: Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma (clinicaltrials.gov)
    P1, N=7, Completed, Theragnostics Ltd | Recruiting --> Completed | N=67 --> 7 | Trial completion date: Apr 2027 --> Mar 2026 | Trial primary completion date: Dec 2026 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    IDH wild-type
    8d
    Sacituzumab Govitecan in Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=32, Recruiting, The University of Texas Health Science Center at San Antonio | Trial completion date: Aug 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    IDH wild-type
    |
    Trodelvy (sacituzumab govitecan-hziy)
    9d
    GBM-MET: Clinical trial on the use of metformin in addition to standard therapy in patients with high-grade glioma (2024-520228-28-00)
    P1/2, N=25, Recruiting, Universita Degli Studi Di Milano Bicocca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH wild-type
    |
    metformin
    11d
    Assessment of the Type and Degree of Genomic Instability in Gliomas. (PubMed, Int J Mol Sci)
    Females, compared to males, exhibited higher MIN in grade 2 tumours and elevated CIN in grade 4 tumours. Our results confirm that genomic instability contributes to tumour progression, MIN being the pivotal factor, and could serve as a prognostic biomarker in malignant gliomas.
    Journal
    |
    MSI (Microsatellite instability)
    |
    IDH wild-type